The global active pharmaceutical ingredients (API) market size reached a value of about USD 212.40 billion in 2022. The market is further expected to grow at a CAGR of about 6.30% during the forecast period of 2023-2031 to reach USD 368.09 billion by 2031.
Active pharmaceutical ingredients (API) refers to the biologically active ingredient of a medicine. Generally, a medicine consists of several components, where the primary component is the API. Other additives are typically known as excipients. Often a drug may include many APIs, and its effect on a patient is dependent on the prescription dosage and may differ from person to person. In combination therapy, two or more active drugs are used to treat various symptoms in multiple ways.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
For a range of large and small suppliers, the global active pharmaceutical ingredients (API) market is highly competitive. Companies involved in its production typically specialise in their manufacturing processes and plan their production on the basis of a combination of internal competencies and business possibilities.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Molecule
Market Breakup by Drug Type
Market Breakup by Type of Manufacturer
Market Breakup by Potency
Market Breakup by API Type
Market Breakup by Therapeutic Application
Market Breakup by End User
Market Breakup by Region
The rising proliferation of chronic conditions has led to a rise in drug demand and, thus, to an increase in the global active pharmaceutical ingredients (API) market growth. In addition, some manufacturers are investing in R&D activities in order to offer higher quality, low-cost APIs, which can help cure illnesses outside the reach of small molecular medicinal products. Therefore, pharmaceutical firms move their manufacturing facilities to developing economies and outsource their operations to maximize production and increase input costs. In addition, there is likely to be a substantial increase in the market for generic APIs as a result of a loss of patent rights for blockbuster drugs worth several billion dollars over the next few years.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The growing number of blockbusters patent expiries is among the key drivers of this industry and provides a substantial chance to generic active pharmaceutical ingredients. In addition, the demand for active pharmaceutical ingredients for bio-based substances has been rising. The global biologics market is currently showing a strong growth, which is catalysed by its high power and ability to treat diseases other than small molecule medicines. This has led to a high demand for APIs and their biosimilar versions of marketed biological drugs. The ageing population, higher expenditure on healthcare, and increased prevalence of lifestyle diseases are the other factors that are catalysing the market development.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Molecule||
|Breakup by Drug Type||
|Breakup by Type of Manufacturer||
|Breakup by Potency||
|Breakup by API Type||
|Breakup by Therapeutic Application||
|Breakup by End User||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Active Pharmaceutical Ingredients (API) Market Overview
3.1 Global Active Pharmaceutical Ingredients (API) Market Historical Value (2016-2022)
3.2 Global Active Pharmaceutical Ingredients (API) Market Forecast Value (2023-2031)
4 Global Active Pharmaceutical Ingredients (API) Market Landscape
4.1 Global Active Pharmaceutical Ingredients (API) Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Active Pharmaceutical Ingredients (API) Product Landscape
4.2.1 Analysis by Molecule
4.2.2 Analysis by Drug Type
4.2.3 Analysis by Type of Manufacturer
4.2.4 Analysis by Potency
4.2.5 Analysis by API Type
4.2.6 Analysis by Therapeutic Application
5 Global Active Pharmaceutical Ingredients (API) Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Active Pharmaceutical Ingredients (API) Market Segmentation
6.1 Global Active Pharmaceutical Ingredients (API) Market by Molecule
6.1.1 Market Overview
6.1.2 Small Molecule
6.1.3 Large Molecule
6.2 Global Active Pharmaceutical Ingredients (API) Market by Drug Type
6.2.1 Market Overview
6.2.2 Branded or Innovative Active Pharmaceutical Ingredients
6.2.3 Generic Active Pharmaceutical Ingredients
6.2.4 Over The Counter (OTC) Drugs
6.3 Global Active Pharmaceutical Ingredients (API) Market by Type of Manufacturer
6.3.1 Market Overview
6.3.2 Captive API Manufacturer
6.3.3 Merchant API Manufacturer
6.4 Global Active Pharmaceutical Ingredients (API) Market by Potency
6.4.1 Market Overview
6.4.2 Low to Moderate
6.4.3 Potent to Highly Potent
6.5 Global Active Pharmaceutical Ingredients (API) Market by API Type
6.5.1 Market Overview
6.5.4 Plant Extracts
6.6 Global Active Pharmaceutical Ingredients (API) Market by Therapeutic Application
6.6.1 Market Overview
6.6.3 CNS & neurology
6.7 Global Active Pharmaceutical Ingredients (API) Market by End User
6.7.1 Pharmaceutical and Biotechnology Industry
6.8 Global Active Pharmaceutical Ingredients (API) Market by Region
6.8.1 Market Overview
6.8.2 North America
6.8.4 Asia Pacific
6.8.5 Latin America
6.8.6 Middle East and Africa
7 North America Active Pharmaceutical Ingredients (API) Market
7.1 Market Share by Country
7.2 United States of America
8 Europe Active Pharmaceutical Ingredients (API) Market
8.1 Market Share by Country
8.2 United Kingdom
9 Asia Pacific Active Pharmaceutical Ingredients (API) Market
9.1 Market Share by Country
10 Latin America Active Pharmaceutical Ingredients (API) Market
10.1 Market Share by Country
11 Middle East and Africa Active Pharmaceutical Ingredients (API) Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.5 South Africa
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
17 Supplier Landscape
17.1 Novartis AG
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.3 Pfizer Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.4 Johnson & Johnson Private Limited
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.6 Teva Pharmaceutical Industries Ltd.
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.7 Bausch Health Companies Inc.
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.8 UCB S.A.
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.9 Sunovion Pharmaceuticals Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.10 Jazz Pharmaceuticals, Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.12 GSK plc
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.13 Takeda Pharmaceutical Company Limited
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.14 Sumitomo Dainippon Pharma Co., Ltd.
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.15 Cadila Pharmaceuticals
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
18 Global Active Pharmaceutical Ingredients (API) Market - Distribution Model (Additional Insight)
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market attained a value of USD 212.40 billion in 2022, driven by the rising healthcare sector.
The market is expected to grow at a CAGR of about 6.30% during the forecast period of 2023-2031 to reach USD 368.09 billion by 2031.
The growth of the market is driven by factors like rising demand from the emerging nations, growing biologics market, increasing healthcare expenditure, and the rising R&D investments.
The key trend guiding the growth of the market includes the upcoming expiry of blockbuster drugs patents, which provides a significant growth potential for generic active pharmaceutical ingredients.
The major regional markets for the product include North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
The major molecules can be categorised into small and large molecule.
The types of the product can be categorised into branded or innovative active pharmaceutical ingredients, generic active pharmaceutical ingredients, and over the counter (OTC) drugs.
The key manufacturers in the market can be divided into captive and merchant API manufacturer.
The potency of the product can be categorised into low to moderate and potent to highly potent.
The product finds wide applications in cardiology, CNS and neurology, oncology, orthopaedic, endocrinology, pulmonology, gastroenterology, nephrology, and ophthalmology, among others.
The end-users of the product include pharmaceutical and biotechnology industry, CROs, and CMOs, among others.
The key players can be categorised into Novartis AG, Sanofi, Pfizer Inc., Johnson & Johnson Private Limited, Abbott, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., UCB S.A., Sunovion Pharmaceuticals Inc., Jazz Pharmaceuticals, Inc., AstraZeneca, GSK plc, Takeda Pharmaceutical Company Limited, Sumitomo Dainippon Pharma Co., Ltd., and Cadila Pharmaceuticals.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.